Background/Aims-The study of graft versus host disease ofthe intestine has significant clinical relevance and may also be a model for other immune mediated intestinal diseases. There presently is no simple non-invasive test that can be used to evaluate graft versus host disease induced intestinal injury in humans or animal models. This study tested the hypothesis that graft versus host disease leads to an increase in host bowel permeability as assessed by the relative urinary excretion of orally administered lactulose and rhamnose. Methods-The urinary excretion ratio of orally administered lactulose and rhamnose was determined daily for two weeks in (Lewis x Brown-Norway) Fl rats with graft versus host disease caused by either the transplantation of parental (Lewis) small bowel or the intraperitoneal injection of parental (Lewis) splenic lymphocytes. Results-Significant twofold to fourfold increases in the lactulose to rhamnose ratio were seen in both small bowel transplant and splenic lymphocyte transfer animals suffering from graft versus host disease during the second postoperative week. This effect occurred sooner in small bowel transplant than in splenic lymphocyte transfer animals (postoperative day 7 versus 11, respectively). The signs of graft versus host disease, including splenomegaly and altered intestinal mucosal architecture, as well as the increased lactulose to rhamnose ratio were significantly attenuated in small bowel transplant animals treated with cyclosporine A (10 mg(kg/day).
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Conclusions-Graft versus host disease is associated with an increase in the lactulose to rhamnose clearance ratio reflecting an increase in host bowel permeability. This increase, along with the signs of systemic graft versus host disease, can be significantly ameliorated by cyclosporine A. The lactulose to rhamnose clearance ratio is a non-invasive technique that can be used to assess the intestinal effects of graft versus host disease and the associated increase in intestinal permeability. (Gut 1996; 39: 291-298) Keywords : graft versus host disease, intestinal permeability, small bowel transplantation, cyclosporine A. Graft versus host disease (GVHD) occurs in up to 75 per cent of patients after bone marrow transplantation and recently has also been described in small bowel transplant recipients.l1 This condition results from the large number of lymphocytes present in both bone marrow and small bowel grafts that recognise the host tissue as foreign.5 In addition to the cutaneous effects such as alopecia and rash, GVHD commonly affects the intestine. An accurate diagnosis of GVHD can be difficult to establish when it affects the gastrointestinal tract because of its relatively non-specific symptomatology. Upper intestinal or rectal endoscopy and biopsy can aid in the diagnosis, but pose significant risks especially when performed repetitively to monitor disease progression. Similar difficulties are encountered in the experimental laboratory, where assessment of intestinal GVHD in animal models usually requires death of the animal. A minimally invasive test could be very useful in the appropriate clinical or experimental setting to diagnose intestinal GVHD or monitor response to treatment.
A relatively non-invasive method of assessing small bowel injury is the measurement of intestinal permeability using orally administered, non-metabolised, and minimally absorbed sugars, such as lactulose and rhamnose. Increases in the ratio of intestinal lactulose to rhamnose permeation and subsequent urinary clearance (LIR) have been described in other immune mediated intestinal illnesses, such as Crohn's disease.68 It was hypothesised that a similar increase in LIR would be seen in GVHD induced injury of the intestine. Such increases in intestinal permeability in GVHD after bone marrow transplantation have already been suggested using radioactive tracer techniques, but these studies have either been anecdotal or complicated by concurrent chemotherapy, which itself is known to increase bowel permeability.9 10 Small bowel transplantation has also been associated with increased intestinal permeability, but this has been in patients or animal models where the surgical manipulation of the intestine itself, malnutrition or simultaneous rejection phenomenon could have been responsible. 1 " 12 We therefore undertook to study the IJR GVHD was produced by either the auxiliary transplantation of small bowel (Fig 1) All animals had the permeability of their native (in situ) bowel assessed daily for two weeks after transplantation using the lactulose/ rhamnose (LIR) clearance technique (see below). Food cups were weighed daily to assess food consumption. Animals were weighed and inspected daily for signs of GVHD (cutaneous erythema, alopecia, weight loss, and dermatitis). Fourteen days after grafting or sham operation, animals were killed by exsanguination under ether anaesthesia. Spleens were weighed and segments of bowel harvested for histology to confirm the presence of intestinal GVHD.
Technique of small bowel transplantation
The technique of small bowel transplantation has been previously described.13 Briefly, small bowel from proximal jejunum to terminal ileum was harvested from the donor and subsequently anastomosed in an auxiliary fashion to the recipient's aorta and vena cava. The proximal and distal ends of the graft were brought out as stomas, creating an auxiliary Thiry-Villa loop. The animal's native bowel was left intact for subsequent bowel permeability assessment (Fig 1) .
Splenic lymphocyte transplantation Spleens were harvested from Lew rats using aseptic technique and placed into sterile Dulbecco's phosphate buffered saline (D-PBS, GIBCO BRL, Life Technologies, Grand Island, NY). Tissue was gently minced using forceps and the resultant suspension passed through a 70 ,um nylon mesh filter (Falcon, Becton Dickinson, Franklin Lakes, NJ). Red cells were lysed by the addition of 15 ml of red cell lysing buffer (Sigma, St Louis, MO). Spleen cells were suspended with D-PBS in a 50 cc conical tube and centrifuged for eight minutes at 200 g in a refrigerated centrifuge. The supematant was discarded, the pellet washed two more times, and finally brought up to 10 cc with D-PBS. A cell count was done using a haemocytometer and trypan blue exclusion to determine viability. Animal weight, food consumption, spleen and histological data were statistically evaluated using paired Student's t test for comparisons within groups and unpaired Student's t test for comparisons between groups. All t tests were two tailed. Significance was considered achieved when p@O.O5.
The LR values from all the animals in each experimental group for each day were combined yielding a group mean and standard error for each day. It was noted that all animals who underwent operative manipulation (Sham-op, SBTX-GVHD, SBTx-CsA) had a transient increase in the LR ratio three to six days after surgery (see Fig 7) . This was felt to be a side effect of the operation because it was absent in unoperated animals (Un-op, Spl-GVHD) and a similar effect has been noted in human studies. 2' 22 To eliminate this variable, a six day postoperative washout period was arbitrarily set and LR data were statistically compared only during the postoperative day 7-13 period (inclusive). This time period also coincided with the clinical manifestations of GVHD in the animals (see below). The LIR data for this entire 7-13 day period for each group were then statistically compared using repeated measures analysis of variance as however, there were no hair or mucous membrane changes.
Food consumption/weight changes Figure 3 shows the mean daily food consumption for each of the groups during the first and second 7 day postoperative periods of the experiment. Food consumption during the first week was very similar, but significantly depressed in those animal groups that underwent surgery compared with those animal groups that did not have surgery. Food consumption during the second week returned to control levels in all animal groups, except the Spl-GVHD group in which there was a significant decline. This decrease in food intake may have accounted, in part, for the concurrent rapid weight loss seen in this animal group. The weight loss seen in the SBTx-GVHD and SBTX-CsA groups during the second week, however, could not be attributed to decreased dietary intake.
Spleen weights
Relative and absolute spleen weights confirmed the presence of GVHD in the experimental groups and the efficacy of CsA treatment in treating GVHD in animals with small bowel transplants (Fig 4) . nent. The Un-op group gained an Intestinal histology cant amount of weight during the two There were significant reductions in villus eriod, while the Sham-op group had a height and increases in crypt depth in SBTx-GVHD animals compared with Sham-op controls in the proximal, mid, and distal regions of SpB-GVHD (n = 9) the small bowel confirming the effects of GVHD Un-op (n = 8) on the host intestine (Fig 5) . In SBTx-GVHD Lactulose/rhamnose bowel permeability Unoperated control animals (Un-op group) showed very consistent mean L/R ratios from day to day during the two week experimental periods (Fig 7) . Sham-op L/R ratios were (1 It is noteworthy that there was a similar pattern of weight loss in the SBTx-CsA animals who also had control levels of food intake but did not manifest overt signs of GVHD. This suggests that either CsA itself had cachexia inducing effects, or that CsA imperfectly treated the GVHD. The latter is probably the case as firstly, the LR ratios did not return completely to control values in the SBTx-CsA group and secondly, a subsequent group of six animals injected daily with CsA (10 mg/kg) had a mean weight after 14 days virtually identical to their mean starting weight (103 (3.5)%). The weight loss seen in the SBTxCsA animals also disputes the possibility that the significant increases in the IR ratios seen in the GVHD groups of animals were simply due to generalised nutritional deterioration causing intestinal atrophy and injury, because the SBTx-CsA group had a relatively low L/R ratio associated with significant weight loss.
The increased L/R ratio seen in this study was significant and presents the sugar clearance technique as a comparatively noninvasive method by which to follow GVHD injury in the controlled laboratory or clinical setting. Assessment of treatment directed at ameliorating intestinal GVHD injury could be accomplished, in part, by repetitive measurement of the IhR clearance ratio. Such a study in Crohn's disease patients showed an increased lactulose/rhamnose ratio in those with active disease, which decreased when patients were treated and became clinically improved.6 It would be tempting to suggest that the lactulose/rhamnose measurement could provide a non-invasive method by which to diagnose intestinal GVHD in patients undergoing bone marrow or small bowel transplantation. Limitations on the applicability of the technique may exist, however, as many other factors have been associated with increased bowel permeability. These include surgery, chemotherapy, neoplasia, sepsis, and malnutrition, many of which could also be present in the patient with GVHD.23 [35] [36] [37] Repetitive IJR measurements may none the less be clinically useful in the individual GVHD patient by providing an improving or deteriorating trend that could minimise the need for more morbid endoscopic biopsy procedures. In this regard, the hR technique has significant advantages over other techniques of bowel permeability measurement, especially those using radioactive tracers, as it can be repetitively applied in the clinical arena with minimal risk.10 In the controlled laboratory setting, the [R ratio could similarly be effective. Therapeutic interventions aimed at decreasing intestinal GVHD injury, such as was done here with CsA, could be assessed in animals on a daily basis without the need for death.
The clinical manifestations of GVHD in the SBTx-GVHD and the Spl-GVHD groups were similar, but both the IhR and intestinal histology data suggest that a more severe intestinal injury occurred in the SBTx-GVHD animals. Crypt elongation occurred in proximal, mid, and distal small bowel in the SBTx-GVHD animals, but was present only in the proximal portions of the bowel in Spl-GVHD animals. The IIR increase appeared sooner in SBTx-GVHD animals compared with Spl-GVHD animals (day 7 v 11, respectively). The disparity in food consumption between the Spl-GVHD and SBTx-GVHD animals during the second week also suggest that GVHD after SBTx may be different than that seen with splenocyte transfer. Such differences may be related to the finding that lymphocytes from the intestine tend to 'home' back to the gut.38 GVHD intestinal injury after SBTx may be greater than that caused by peripheral or splenic lymphocyte transfer because of this trafficking phenomenon, directing and preferentially localising the donor enteric lymphocytes and injury to the host bowel. This suggests that data regarding GVHD mediated intestinal injury obtained from clinical bone marrow transplantation patients may not be directly applicable to the increasing number of patients receiving small bowel transplants. Further clinical and animal studies are warranted, evaluating this concept of lymphocyte homing and host intestinal injury after bowel transplantation.
In summary, using both splenocyte and small bowel transplant models of GVHD, increases in host bowel permeability, as measured by the lactulose/rhamnose urinary clearance technique were observed. This increase in the lactulose/rhamnose ratio was attenuated by treatment of small bowel transplant animals with cyclosporine A. These data suggest that the lactulose/rhamnose urinary clearance assay may provide a non-invasive method by which to assess intestinal injury and the effect of treatment in GVHD mediated injury of the bowel.
